Search research articles
Contact Us
Filters
Showing results (841-850 of 973) with videos related to
Page
of 98
Sort By:
Pancreas
|
September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy
Reza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2006
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
Christopher H Crane, Lee M Ellis, James L Abbruzzese, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 22, 2008
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer
Tse-Kuan Yu, Priya R Bhosale, Christopher H Crane, et al.
Plos One
|
December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications
Chaitanya R Churi, Rachna Shroff, Ying Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
Scott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
Ryan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Annals of Surgical Oncology
|
January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
Ching-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2017
Molecular spectrum of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PIK3CA</i>, <i>TP53</i>, and <i>APC</i> somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern
Humaid O Al-Shamsi, Jeremy Jones, Yazan Fahmawi, et al.
Cancers
|
October 16, 2024
The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy
Mehran Taherian, Matthew H G Katz, Laura R Prakash, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
September 3, 2013
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
Ching-Wei D Tzeng, Aparna Balachandran, Mediha Ahmad, et al.
Page
of 98
Search research articles
Search
Showing results (841-850 of 973) with videos related to
Sort By:
Page
of 98
Pancreas
|
September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy
Reza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2006
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
Christopher H Crane, Lee M Ellis, James L Abbruzzese, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 22, 2008
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer
Tse-Kuan Yu, Priya R Bhosale, Christopher H Crane, et al.
Plos One
|
December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications
Chaitanya R Churi, Rachna Shroff, Ying Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
Scott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
Ryan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Annals of Surgical Oncology
|
January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
Ching-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2017
Molecular spectrum of <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PIK3CA</i>, <i>TP53</i>, and <i>APC</i> somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern
Humaid O Al-Shamsi, Jeremy Jones, Yazan Fahmawi, et al.
Cancers
|
October 16, 2024
The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy
Mehran Taherian, Matthew H G Katz, Laura R Prakash, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
September 3, 2013
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
Ching-Wei D Tzeng, Aparna Balachandran, Mediha Ahmad, et al.
Page
of 98